Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

have been licensed to major pharmaceutical companies. Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with several pharmaceutical companies, including Boehringer Ingelheim, Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK), Mylan, UCB and Otsuka. Vectura has been included in the FTSE 250 index since 23 March 2009. For further information, please visit Vectura's website at http://www.vectura.com

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's or Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 According to a ... (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application ... Forecast to 2020", published by MarketsandMarkets, the global Neuromodulation Market ... to reach $6.20 Billion by 2020, at a CAGR of ... 8 4 market data T ...
(Date:7/2/2015)... July 2, 2015 Numotion,s Board of Directors ... that Tamas Feitel has joined the Company ... after a highly successful 18 year career at GE ... strategy, profitability, and productivity to result in significant industry ... was Chief Financial Officer for GE Healthcare Global Services, ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/8mfjxh/2015_new ) has announced the addition of ... Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, ... 2015 New Frontiers in Clinical ... Competitive Landscape is a new seven-country strategic ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... COUNTY, Calif., Nov. 23 Beckman Coulter, Inc. (NYSE: ... marketer of products that simplify, automate, and innovate complex ... vice president of strategy, will present at the Piper ... 12:00 p.m. (ET). , (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) , ...
... , NEW YORK, Nov. ... report is available in its catalogue. , U.S. ... http://www.reportlinker.com/p0164740/US-Market-for-PACS-and-EMR.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , In 2008, ... billion, representing an increase of 6.7% over 2007. This ...
Cached Medicine Technology:Reportlinker Adds U.S. Market for PACS and EMR 2Reportlinker Adds U.S. Market for PACS and EMR 3Reportlinker Adds U.S. Market for PACS and EMR 4Reportlinker Adds U.S. Market for PACS and EMR 5Reportlinker Adds U.S. Market for PACS and EMR 6Reportlinker Adds U.S. Market for PACS and EMR 7Reportlinker Adds U.S. Market for PACS and EMR 8Reportlinker Adds U.S. Market for PACS and EMR 9Reportlinker Adds U.S. Market for PACS and EMR 10Reportlinker Adds U.S. Market for PACS and EMR 11Reportlinker Adds U.S. Market for PACS and EMR 12Reportlinker Adds U.S. Market for PACS and EMR 13Reportlinker Adds U.S. Market for PACS and EMR 14
(Date:7/3/2015)... ... July 03, 2015 , ... ... registration for a new SEO training system called "Page One Engine" . ... traffic generation has received glowing reviews from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... its 2015 Annual Conference , the premiere continuing education and networking ... Orlando at SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts ...
(Date:7/3/2015)... ... ... Scientists at several top US cancer centers believe they now know why ... here to read the complete story , just posted on the Surviving Mesothelioma website. ... and New York University exposed mice with a mutation on the tumor suppressor gene ...
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich ... be held from March 4th - 6th, the 2016 (a previous announcement had stated ... Designed to take participants from the basic training and fundamentals of nasal surgery through ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national president recruitment for Regional ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
Breaking Medicine News(10 mins):Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3
... Senate to Quickly Pass this Important Lifesaving LegislationWASHINGTON, ... American Lung Association President and CEO:Today in Washington, ... favor with a strong bipartisan majority for the ... Family Smoking Prevention and Tobacco Control Act (HR ...
... The California Association of Health Plans (CAHP) is ... Awareness Day by increasing awareness about the wide ... for autism."California health plans understand the inherent challenges ... mental health conditions," said CAHP Interim President Charles ...
... (omega-3s), namely EPA and DHA found in seafood and ... benefits, but evidence of other benefits continues to stack ... menopausal women and healthier weight loss in obese dieters ... these topics are summarized in the March 2009 ...
... Excess amounts of a naturally fluorescent molecule found in ... for cancer, according to bioengineers. , NADH, or nicotinamide ... molecule necessary for the functioning of an enzyme -- ... power plant, or mitochondria. It fuels a series of ...
... Varian Medical Systems (NYSE: VAR ) today ... growth and innovation in life-saving technology utilizing X-ray energy ... , Varian Medical Systems emerged as a ... of Varian Associates, a 51-year-old Silicon Valley pioneer, into ...
... Take Place on May 2; ... Follow on May 9 LOS ANGELES, April 2 Revlon (NYSE: ... spokeswomen Jennifer Connelly and Jessica Alba along with NBC late night ... in New York taking place on Saturday, May 2, 2009 , ...
Cached Medicine News:Health News:U.S. House of Representatives Again Votes with a Strong Bipartisan Majority in Favor of Granting the U.S. FDA Regulatory Control Over Tobacco Products 2Health News:California Association of Health Plans Recognizes World Autism Awareness Day by Highlighting Medical Services Plans Provide 2Health News:Omega-3s May Benefit Newborns, Menopausal Women and Obese Individuals 2Health News:Naturally fluorescent molecules may serve as cancer biomarker 2Health News:Naturally fluorescent molecules may serve as cancer biomarker 3Health News:Varian Medical Systems to Celebrate Tenth Anniversary and Decade of Growth 2Health News:Varian Medical Systems to Celebrate Tenth Anniversary and Decade of Growth 3Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 2Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 3Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 4
... PRECISION represents a major advance ... be,tightly focused to cover pain. This ... where you need it, anywhere along ... of independent current sources for each ...
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: